financetom
Business
financetom
/
Business
/
South Korea watchdog questions purpose of Hanwha Aerospace's $2.5 billion share issue
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
South Korea watchdog questions purpose of Hanwha Aerospace's $2.5 billion share issue
Mar 31, 2025 10:32 PM

SEOUL (Reuters) -South Korea's financial market watchdog said on Tuesday that Hanwha Aerospace needed to better explain how a proposed 3.6 trillion won ($2.46 billion) equity raising fits with a broader plan to restructure the company.

The Financial Supervisory Service (FSS) last week blocked the defence company's controversial capital raising plans on the grounds its filing lacked information needed for shareholders to make rational investment decisions, and ordered it to submit a revised filing.

"The ownership restructuring of affiliates and its relevance to the share issue plan, as well as the impact of the restructuring on the firm should be sufficiently noted," FSS Senior Deputy Governor Hahm Yong-il told a briefing.

On March 21, a day after the plan was announced, shares in Hanwha Aerospace posted their worst session since early November 2016, sinking 13%, as analysts raised questions over the intent and need for raising capital.

Hanwha Group, South Korea's seventh-largest conglomerate, announced on Monday that Chairman Kim Seung Youn was giving an 11.32% stake in Hanwha Aerospace's parent, Hanwha Corp, to his sons as part of a succession process.

Hanwha Aeropsace said on Tuesday its executives, including one of Kim's sons, purchased about 9 billion won worth of shares in the company to show their will to raise shareholder value.

The controversy over Hanwha's share issue plan was the latest in a series of large capital-raising plans, including ones by battery maker Samsung SDI and Korea Zinc, that were met by investor criticism amid South Korea's broader push for corporate governance reforms.

Shares in Hanwha Aerospace jumped 7.5%, while the benchmark KOSPI stock index was up 1.8% as of 0445 GMT.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Foreigners add net $32.7 bln to EM portfolios in March -IIF
Foreigners add net $32.7 bln to EM portfolios in March -IIF
Apr 23, 2024
NEW YORK, April 23 (Reuters) - Foreigners added about $32.7 billion to their emerging market portfolios in March, a fifth consecutive month of overall foreign net flows to EMs, the Institute of International Finance said on Tuesday. The IIF banking trade group said flows were positive for both bonds and equities last month, with equities absorbing $10.2 billion and debt...
Starbucks Faces Near-Term Pressures, But Long-Term Outlook Remains Positive, UBS Says
Starbucks Faces Near-Term Pressures, But Long-Term Outlook Remains Positive, UBS Says
Apr 23, 2024
03:08 PM EDT, 04/23/2024 (MT Newswires) -- Starbucks' ( SBUX ) 2024 outlook will likely be affected by near-term pressures, but it remains well-positioned in the long term due to strong customer brand affinity and an attractive growth profile, UBS said in a note emailed Tuesday. Challenges in the US stem from protests related to Middle East conflict and pressure...
--Street Color: L3Harris Technologies to Reportedly Eliminate 5% of Workforce in 2024
--Street Color: L3Harris Technologies to Reportedly Eliminate 5% of Workforce in 2024
Apr 23, 2024
03:10 PM EDT, 04/23/2024 (MT Newswires) -- (Street Color news is derived from real time discussions with market professionals globally subscribed to the Street Color Premium Chat service on Bloomberg IB Chat and the ICE IM. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.) Price: 208.32, Change: +0.18, Percent...
FDA Approves Novartis' Lutathera As First Therapy For Pediatric Patients With Gastroenteropancreatic Neuroendocrine Tumors
FDA Approves Novartis' Lutathera As First Therapy For Pediatric Patients With Gastroenteropancreatic Neuroendocrine Tumors
Apr 23, 2024
Tuesday, Novartis AG ( NVS )  received FDA approval for its Lutathera (lutetium Lu 177 dotatate / INN: lutetium (177Lu) oxodotreotide) for pediatric patients 12 years and older with somatostatin receptor-positive (SSTR+) gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut NETs.  This approval makes Lutathera the first therapy specifically reviewed and approved for use in pediatric patients with GEP-NETs. Related: Novartis Stock Gains On European Drugmaker’s Q1 Earnings...
Copyright 2023-2026 - www.financetom.com All Rights Reserved